新光药业(300519) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥91,987,344.20, representing a 6.02% increase compared to the same period last year[5]. - Total operating revenue for the third quarter reached ¥262,451,469.03, an increase of 6.4% compared to ¥246,270,270.66 in the same period last year[21]. - Net profit for the quarter was ¥89,396,702.14, representing a 1.6% increase from ¥87,978,147.82 in the previous year[22]. - Net profit attributable to shareholders decreased by 7.66% to ¥28,591,838.48 in Q3 2022[5]. - The basic earnings per share for Q3 2022 was ¥0.18, down 7.66% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.56, slightly up from ¥0.55 in the same quarter last year[23]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥925,596,021.86, a decrease of 0.73% from the end of the previous year[5]. - The total assets amount to 925,596,021.86 CNY, slightly down from 932,403,805.04 CNY at the beginning of the year[18]. - The company has a total of 776,253,612.97 CNY in current assets as of September 30, 2022, a decrease from 785,915,254.00 CNY at the beginning of the year[18]. - Total liabilities stood at ¥86,288,927.95, a slight increase from ¥86,186,733.69 year-over-year[22]. - The total liabilities include accounts payable of 47,711,673.11 CNY, down from 56,114,995.19 CNY[18]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥93,520,425.37, down 6.46% compared to the previous year[5]. - Cash generated from operating activities was ¥252,682,384.12, compared to ¥231,357,763.69 in the previous period[25]. - Net cash flow from operating activities was CNY 93,520,425.37, down from CNY 99,980,133.44, indicating a decrease of about 6% year-over-year[26]. - Investment cash inflow reached CNY 318,217,151.28, compared to CNY 232,075,620.45 in the same period last year, marking an increase of approximately 37%[26]. - The net cash flow from investment activities was CNY 8,417,944.69, a significant recovery from a negative CNY 40,699,483.27 in the previous year[26]. - Total cash and cash equivalents at the end of the period amounted to CNY 599,606,165.97, up from CNY 555,128,438.39, representing an increase of about 8%[26]. - The company reported a net increase in cash and cash equivalents of CNY 5,938,370.06, contrasting with a decrease of CNY 36,719,349.83 in the prior year[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,533[12]. - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[12]. - Wang Yuejun's locked shares remain at 45,900,000, with a commitment to not transfer more than 25% of his holdings annually[14]. - The company’s major shareholder, Shengzhou He Feng Investment Co., Ltd., reduced its holdings by 8,011,242 shares, representing a 5.007% decrease in total share capital[15]. Expenses - Total operating costs amounted to ¥160,326,179.06, up from ¥144,876,549.66, reflecting a year-over-year increase of 10.6%[21]. - Research and development expenses increased to ¥11,675,620.43, compared to ¥9,450,187.40, marking a 23.0% rise year-over-year[22]. - The company reported a 34.18% increase in financial expenses, totaling -¥8,477,860.27, primarily due to increased bank deposit interest[9]. Audit and Reporting - The company did not undergo an audit for the third quarter report[27]. - The report was released by the board of directors on October 26, 2022[27].